Trial Profile
Phase II Study: Therapy With Bortezomib + Lenalidomide + Dexamethasone With Lenalidomide + Dexamethasone as Post Transplant Consolidation and Maintenance for Patients With Symptomatic Multiple Myeloma Following Autologous Transplantation
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Mar 2015
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Lenalidomide (Primary) ; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 10 Feb 2015 New trial record